72956-09-3 Usage
Description
Carvedilol, also known as Coreg, is a vasodilating beta-blocker with a unique pharmacological profile. It is a nonselective β-adrenergic blocker with α1-blocking activity, possessing β-blocking activity that is 10to 100-fold of its α-blocking activity. Carvedilol is a colorless crystalline solid that is well-tolerated and has renal-sparing effects.
Uses
Used in Pharmaceutical Industry:
Carvedilol is used as an antihypertensive agent for the treatment of congestive heart failure. It helps manage the symptoms by lowering blood pressure and decreasing total vascular resistance without causing reflex tachycardia, which is usually associated with vasodilators.
Used in Veterinary Medicine:
Carvedilol is used in veterinary applications for the treatment of mild or moderate heart failure of ischemic or cardiomyopathic origin in animals.
Used in Antimicrobial Applications:
Carvedilol is used as an antibacterial agent, providing an additional layer of treatment options for certain bacterial infections.
Used in Athletic Performance Enhancement:
Formulations containing carvedilol have been used to enhance physical performance in athletes, although this use is not medically recommended and may have legal implications.
Used in Analytical Forensic Applications:
Carvedilol is used as an analytical reference standard, categorized as a β-adrenergic receptor antagonist and vasodilator, for forensic analysis and research purposes.
Used in Research:
Carvedilol serves as a general research tool for studying the effects of β-blockers and their potential applications in various medical conditions, particularly in the management of congestive heart failure.
Manufacturing Process
1-(9H-Carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-2-propanol
may be synthesized by the method of preparation of S-(-)-(1-carbazol-4-
yloxy)-3-[2-(2-methoxyphenoxy)]ethylaminopropan-2-ol (Patent US
4,697,022 and 4,824,963).27.5 g 4-hydroxycarbazole are dissolved in a mixture of 150 ml 1 N aqueous
sodium hydroxide solution and 70 ml dimethylsulfoxide. To this is added at
ambient temperature 13.9 g epichlorohydrin, followed by stirring for 18 hours
at ambient temperature. 280 ml water are then added thereto, followed by
stirring for 15 min and filtering off with suction. The filter residue is washed
with 0.1 N aqueous sodium hydroxide solution and water and subsequently
dissolved in methylene chloride. The methylene chloride solution is dried over
anhydrous sodium sulfate, treated with active charcoal and floridin and
evaporated. 4-(2,3-Epoxypropoxy)-carbazole is purified by recrystallising twice
from ethyl acetate. From the mother liquors there are isolated a further 4-
(2,3-epoxypropoxy)-carbazole.10 g 4-(2,3-epoxypropoxy)-carbazole are, together with 13.97 g o-methoxyphenoxyethylamine, heated under reflux in 70 ml isopropanol for 2
hours. The solvent is evaporated off and the residue is stirred for 2 hours with
a mixture of 115 ml toluene, 35 ml cyclohexane and 40 ml ethyl acetate.
After filtering off with suction, the (1-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)]-ethylaminopropan-2-ol is recrystallised from 150 ml ethyl
acetate.
Therapeutic Function
Beta-adrenergic blocker
Biological Activity
Potent β -adrenoceptor and α 1 -adrenoceptor antagonist (K i values are 0.81, 0.96 and 2.2 nM for β 1 -, β 2 - and α 1 -adrenoceptors respectively) that displays antihypertensive and peripheral vasodilatory activity. Blocks cardiac inward-rectifier K + (K IR ) channels, voltage-dependent Ca 2+ channels and exhibits antioxidant properties at higher concentrations.
Biochem/physiol Actions
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.
Clinical Use
Carvedilol is also unique in that it possesses antioxidantactivity and an antiproliferative effect on vascular smoothmuscle cells. It thus has a neuroprotective effect and the abilityto provide major cardiovascular organ protection. It isused in treating hypertension and congestive heart failure.
Veterinary Drugs and Treatments
Carvedilol may be useful as adjunctive therapy in the treatment
of heart failure (dilated cardiomyopathy) in dogs. There is a fair
amount of controversy at present among veterinary cardiologists as
to whether this drug will find a therapeutic niche.
in vitro
carvedilol potently inhibited fe2+-initiated lipid peroxidation in rat brain homogenate with an ic50 of 8.1 μm. in rat brain homogenate, carvedilol protected against fe2+-induced α-tocopherol depletion with an ic50 of 17.6 μm. carvedilol dose-dependently decreased the intensity of the dmpo-oh signal, with an ic50 of 25 μm [1]. carvedilol prevented vascular smooth muscle cell migration, proliferation, and neointimal formation following vascular injury. in human cultured pulmonary artery vascular smooth muscle cells, carvedilol (0.1-10 μm) concentration-dependently inhibited the mitogenesis stimulated by platelet-derived growth factor, epidermal growth factor, thrombin, and serum, with ic50 values ranging from 0.3 to 2.0 μm. carvedilol concentration-dependently inhibited vascular smooth muscle cell migration induced by platelet-derived growth factor with an ic50 value of 3 μm [3].
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial
depression and bradycardia; increased risk of
bradycardia, myocardial depression and AV block
with amiodarone; increased risk of myocardial
depression and bradycardia with flecainide.
Antibacterials: concentration reduced by rifampicin.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Antihypertensives; enhanced hypotensive effect;
increased risk of withdrawal hypertension with
clonidine; increased risk of first dose hypotensive
effect with post-synaptic alpha-blockers such as
prazosin.
Antimalarials: increased risk of bradycardia with
mefloquine.
Antipsychotics enhanced hypotensive effect with
phenothiazines.
Calcium-channel blockers: increased risk of
bradycardia and AV block with diltiazem;
hypotension and heart failure possible with
nifedipine and nisoldipine; asystole, severe
hypotension and heart failure with verapamil.
Ciclosporin: increased trough concentration, reduce
dose by 20% in affected patients.
Cytotoxics: possible increased risk of bradycardia
with crizotinib.
Diuretics: enhanced hypotensive effect.
Fingolimod: possibly increased risk of bradycardia.
Moxisylyte: possible severe postural hypotension.
Sympathomimetics: severe hypertension with
adrenaline and noradrenaline and possibly with
dobutamine.
Metabolism
Carvedilol is subject to considerable first-pass metabolism
in the liver; the absolute bioavailability is about 25%. It
is extensively metabolised in the liver, primarily by the
cytochrome P450 isoenzymes CYP2D6 and CYP2C9,
and the metabolites are excreted mainly in the bile.
Check Digit Verification of cas no
The CAS Registry Mumber 72956-09-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,9,5 and 6 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 72956-09:
(7*7)+(6*2)+(5*9)+(4*5)+(3*6)+(2*0)+(1*9)=153
153 % 10 = 3
So 72956-09-3 is a valid CAS Registry Number.
InChI:InChI=1/C24H26N2O4.C4H6O6/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;5-1(3(7)8)2(6)4(9)10/h2-12,17,25-27H,13-16H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)
72956-09-3Relevant articles and documents
In-situ and one-step preparation of protein film in capillary column for open tubular capillary electrochromatography enantioseparation
Li, Ling,Xue, Xuqi,Zhang, Huige,Lv, Wenjuan,Qi, Shengda,Du, Hongying,Manyande, Anne,Chen, Hongli
supporting information, p. 2139 - 2142 (2021/04/07)
In this work, the phase-transitioned BSA (PTB) film using the mild and fast fabrication process adhered to the capillary inner wall uniformly, and the fabricated PTB film-coated capillary column was applied to realize open tubular capillary electrochromatography (OT-CEC) enantioseparation. The enantioseparation ability of PTB film-coated capillary was evaluated with eight pairs of chiral analytes including drugs and neurotransmitters, all achieving good resolution and symmetrical peak shape. For three consecutive runs, the relative standard deviations (RSD) of migration time for intra-day, inter-day, and column-to-column repeatability were in the range of 0.3%–3.5%, 0.2%–4.9% and 2.1%–7.7%, respectively. Moreover, the PTB film-coated capillary column ran continuously over 300 times with high separation efficiency. Therefore, the coating method based on BSA self-assembly supramolecular film can be extended to the preparation of other proteinaceous capillary columns.
Preparation and evaluation of a triazole-bridged bis(β-cyclodextrin)–bonded chiral stationary phase for HPLC
Shuang, Yazhou,Liao, Yuqin,Wang, Hui,Wang, Yuanxing,Li, Laisheng
, p. 168 - 184 (2019/11/25)
A triazole-bridged bis(β-cyclodextrin) was synthesized via a high-yield Click Chemistry reaction between 6-azido-β-cyclodextrin and 6-propynylamino-β-cyclodextrin, and then it was bonded onto ordered silica gel SBA-15 to obtain a novel triazole-bridged bis (β-cyclodextrin)–bonded chiral stationary phase (TBCDP). The structures of the bridged cyclodextrin and TBCDP were characterized by the infrared spectroscopy, mass spectrometry, elemental analysis, and thermogravimetric analysis. The chiral performance of TBCDP was evaluated by using chiral pesticides and drugs as probes including triazoles, flavanones, dansyl amino acids and β-blockers. Some effects of the composition in mobile phase and pH value on the enantioseparations were investigated in different modes. The nine triazoles, eight flavanones, and eight dansyl amino acids were successfully resolved on TBCDP under the reversed phase with the resolutions of hexaconazole, 2′-hydroxyflavanone, and dansyl-DL-tyrosine, which were 2.49, 5.40, and 3.25 within 30 minutes, respectively. The ten β-blockers were also separated under the polar organic mode with the resolution of arotinolol reached 1.71. Some related separation mechanisms were discussed preliminary. Compared with the native cyclodextrin stationary phase (CDSP), TBCDP has higher enantioselectivity to separate more analytes, which benefited from the synergistic inclusion ability of the two adjacent cavities and bridging linker of TBCDP, thereby enabling it a promising prospect in chiral drugs and food analysis.
Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents
Xu, Yao,Chen, Shujun,Cao, Ying,Zhou, Pingzheng,Chen, Zhipeng,Cheng, Kui
, p. 253 - 266 (2018/05/29)
Toll-like receptor 4 (TLR4) initiates innate immune response to release inflammatory cytokines and has been pathologically linked to variety of inflammatory diseases. Recently, we found that Carvedilol, as the classic anti-heart failure and anti-inflammatory clinic drug, could inhibit the TLR4 signaling in the TLR4 overexpressed cells. Herein, we have designed and synthesized a small library of novel Carvedilol derivatives and investigated their potential inhibitory activity. The results indicate that the most potent compound 8a (SMU-XY3) could effectively inhibited TLR4 protein and the LPS triggered alkaline phosphatase signaling in HEK-Blue hTLR4 cells. It down regulated the nitric oxide (NO) in both RAW264.7 cells and BV-2 microglial cells, in addition to blocking the TNF-α signaling in ex-vivo human peripheral blood mononuclear cells (PBMC). More interestingly, 8a shows higher affinity to hyperpolarization-activated cyclic nucleotide-gated 4 (HCN4) over HCN2, which probably indicates the new application of TLR4 inhibitor 8a in heart failure, coronary heart disease, and other inflammatory diseases.